Please Wait
Applying Filters...
Menu
Xls
2D Structure
Also known as: 1845-11-0, Nafoxidine [inn], Nafoxidinum [inn-latin], Nafoxidina [inn-spanish], 1-[2-[4-(6-methoxy-2-phenyl-3,4-dihydronaphthalen-1-yl)phenoxy]ethyl]pyrrolidine, U-11000a
Molecular Formula
C29H31NO2
Molecular Weight
425.6  g/mol
InChI Key
JEYWNNAZDLFBFF-UHFFFAOYSA-N
FDA UNII
4RIY10WM82

An estrogen antagonist that has been used in the treatment of breast cancer.
1 2D Structure

2D Structure

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
1-[2-[4-(6-methoxy-2-phenyl-3,4-dihydronaphthalen-1-yl)phenoxy]ethyl]pyrrolidine
2.1.2 InChI
InChI=1S/C29H31NO2/c1-31-26-14-16-28-24(21-26)11-15-27(22-7-3-2-4-8-22)29(28)23-9-12-25(13-10-23)32-20-19-30-17-5-6-18-30/h2-4,7-10,12-14,16,21H,5-6,11,15,17-20H2,1H3
2.1.3 InChI Key
JEYWNNAZDLFBFF-UHFFFAOYSA-N
2.1.4 Canonical SMILES
COC1=CC2=C(C=C1)C(=C(CC2)C3=CC=CC=C3)C4=CC=C(C=C4)OCCN5CCCC5
2.2 Other Identifiers
2.2.1 UNII
4RIY10WM82
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Hydrochloride, Nafoxidine

2. Nafoxidine Hydrochloride

3. U 11,100a

4. U 11000a

5. U-11,100a

6. U-11000a

7. U11,100a

8. U11000a

2.3.2 Depositor-Supplied Synonyms

1. 1845-11-0

2. Nafoxidine [inn]

3. Nafoxidinum [inn-latin]

4. Nafoxidina [inn-spanish]

5. 1-[2-[4-(6-methoxy-2-phenyl-3,4-dihydronaphthalen-1-yl)phenoxy]ethyl]pyrrolidine

6. U-11000a

7. Pyrrolidine, 1-(2-(4-(3,4-dihydro-6-methoxy-2-phenyl-1-naphthalenyl)phenoxy)ethyl)-

8. Chembl28211

9. 4riy10wm82

10. Chebi:34881

11. Nsc 70735

12. 1-(2-(p-(3,4-dihydro-6-methoxy-2-phenyl-1-naphthyl)phenoxy)ethyl)pyrrolidine

13. 1-(2-(4-(6-methoxy-2-phenyl-3,4-dihydronaphthalen-1-yl)phenoxy)ethyl)pyrrolidine

14. 1-{2-[4-(6-methoxy-2-phenyl-3,4-dihydronaphthalen-1-yl)phenoxy]ethyl}pyrrolidine

15. Pyrrolidine, 1-(2-(p-(3,4-dihydro-6-methoxy-2-phenyl-1-naphthyl)phenoxy)ethyl)-

16. Pyrrolidine,1-[2-[4-(3,4-dihydro-6-methoxy-2-phenyl-1-naphthalenyl)phenoxy]ethyl]-

17. Nafoxidina

18. Nafoxidinum

19. Nsc70735

20. Brn 1440873

21. Unii-4riy10wm82

22. Spectrum5_000222

23. Nafoxidine [who-dd]

24. 5-20-01-00210 (beilstein Handbook Reference)

25. Bidd:er0063

26. Schembl153125

27. 11100a (*hydrochloride*)

28. Gtpl4263

29. Dtxsid7022386

30. U 11100 (*hydrochloride*)

31. U 11100a (*hydrochloride*)

32. U-11100a (*hydrochloride*)

33. Zinc538045

34. Bdbm50065941

35. Ncgc00188970-01

36. 845n110

37. Q6958201

38. 1-(2-(4-(3,4-dihydro-6-methoxy-2-phenyl-1-naphthalenyl)phenoxy)ethyl)pyrrolidine

39. 1-(2-[4-(6-methoxy-2-phenyl-3,4-dihydro-1-naphthalenyl)phenoxy]ethyl)pyrrolidine #

40. 1-{2-[4-(6-methoxy-2-phenyl-3,4-dihydro-naphthalen-1-yl)-phenoxy]-ethyl}-pyrrolidine

2.4 Create Date
2005-03-25
3 Chemical and Physical Properties
Molecular Weight 425.6 g/mol
Molecular Formula C29H31NO2
XLogP35.8
Hydrogen Bond Donor Count0
Hydrogen Bond Acceptor Count3
Rotatable Bond Count7
Exact Mass425.235479232 g/mol
Monoisotopic Mass425.235479232 g/mol
Topological Polar Surface Area21.7 Ų
Heavy Atom Count32
Formal Charge0
Complexity611
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Pharmacology and Biochemistry
4.1 MeSH Pharmacological Classification

Antineoplastic Agents, Hormonal

Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079) (See all compounds classified as Antineoplastic Agents, Hormonal.)


Estrogen Antagonists

Compounds which inhibit or antagonize the action or biosynthesis of estrogenic compounds. (See all compounds classified as Estrogen Antagonists.)